A study co-authored by Robert Hindes, MD, a researcher and the chief medical officer of BeyondWest Pharmaceuticals of Wilmington, Delaware, examines entecavir therapy and its impact on patients with liver damage resulting from hepatitis B infection. Robert Hindes, MD, and his fellow investigators looked specifically at entecavir therapy taken daily over the long term. The paper considered those patients who had undergone a minimum of 36 months of entecavir therapy and also had a liver biopsy to determine the state of their histological health.
In all, 57 patients met the study’s criteria. Of those patients, over 95 percent exhibited histologic improvement of liver disease following treatment. The percentage includes those individuals with cirrhosis or advanced fibrosis. The authors concluded that individuals who receive entecavir therapy over the long term show regression of liver disease.
The study appeared in Hepatology: Official Journal of the American Association for the Study of Liver Diseases, under the title “Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B.”